查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1909036

植入胰島素幫浦市場規模、佔有率和成長分析（按幫浦類型、儲液器容量、給藥方式、最終用戶、年齡層、適應症、分銷管道和地區分類）－2026-2033年產業預測

Implantable Insulin Pump Market Size, Share, and Growth Analysis, By Pump Type, By Reservoir Size, By Delivery Mode, By End User, By Age Group, By Indication, By Distribution Channel, By Region - Industry Forecast 2026-2033
出版日期: | 出版商: SkyQuest | 英文 188 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球植入胰島素幫浦市場規模預計在 2024 年達到 393.5 億美元，從 2025 年的 480.8 億美元成長到 2033 年的 2,390.9 億美元，在預測期（2026-2033 年）內複合年成長率為 22.2%。

全球植入胰島素幫浦市場正經歷顯著成長，這主要得益於糖尿病盛行率的上升以及對先進胰島素輸注系統需求的不斷成長。患者越來越傾向於選擇持續、精準的胰島素管理，以最大限度地減少血糖值波動和長期併發症。科技進步帶來了更可靠、更人性化的胰島素幫浦設計，而人們對有效糖尿病管理策略的認知不斷提高，也推動了市場擴張。此外，有利的醫療政策和報銷計劃也提高了這些設備的可及性。然而，胰島素幫浦和手術的高成本、發展中國家認知度有限、嚴格的監管要求、潛在的感染風險以及持續維護的需求等挑戰，可能會在短期內阻礙市場成長。

全球植入胰島素幫浦市場按幫浦類型、儲液器容量、輸注方式、最終用戶、年齡層、適應症、通路和地區進行細分。按泵類型分類，市場分為可程式設計植入式泵、閉合迴路泵、開放回路泵、不可程式設計植入式泵和其他類型。依儲液器容量分類，市場分為小容量（<10 mL）、中容量（10-20 mL）、大容量（>20 mL）及其他容量。依輸注方式分類，市場分為持續基礎輸注、餐前大大劑量投藥、基礎-餐前聯合Bolus及其他輸注方式。按最終用戶分類，市場分為醫院、門診手術中心 (ASC)、糖尿病專科診所、居家醫療機構和其他機構。依年齡層別分類，市場分為兒童（<17歲）、成人（18-64歲）及老年人（>65歲）。依適應症分類，市場可分為第1型糖尿病（T1DM）、第2型糖尿病（T2DM）及其他類型。依通路分類，市場可分為兒童（17歲及以下）、成人（18-64歲）及老年人（65歲以上）。依地區分類，市場可分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球植入胰島素幫浦市場促進因素

全球植入胰島素幫浦市場的主要促進因素之一是糖尿病（尤其是第1型糖尿病）在全球範圍內的日益普及。人們對糖尿病管理和維持理想血糖值重要性的認知不斷提高，推動了對植入胰島素幫浦等先進糖尿病護理解決方案的需求。這些設備不僅透過持續輸注胰島素提升了患者的便利性，還能改善血糖控制並降低糖尿病併發症的風險。此外，幫浦設計的技術進步和創新也進一步推動了尋求有效治療方案的患者群體對這些設備的接受度。

限制全球植入胰島素幫浦市場的因素

全球植入胰島素幫浦市場的主要限制因素之一是這些先進醫療設備的高成本。除了初始購買價格外，後續的維護、耗材和醫療諮詢等費用也可能成為許多患者的負擔，尤其是在醫療資源有限的發展中地區。此外，保險覆蓋範圍往往不穩定，也為尋求使用這些創新技術的患者帶來了經濟障礙。這項經濟挑戰可能會阻礙植入市場成長潛力，進而影響製造商和尋求有效糖尿病管理解決方案的終端用戶。

全球植入胰島素幫浦市場趨勢

先進技術的整合，尤其是與持續血糖監測（CGM）系統的結合，是全球植入胰島素幫浦市場的一大趨勢。這種協同效應推動了所謂「人工胰臟解決方案」或「閉合迴路系統」的發展，這些系統能夠根據即時血糖值讀數自動調節胰島素劑量。這些創新不僅提高了治療的精確度，還簡化了使用者的日常管理，減少了持續監測和手動輸入的需求。因此，市場對這些智慧植入式設備的需求不斷成長，這些設備增強了患者的信心，並改善了糖尿病的整體管理效果。

目錄

介紹

  • 調查目標
  • 調查範圍
  • 定義

調查方法

  • 資訊收集
  • 二手資料和一手資料方法
  • 市場規模預測
  • 市場假設與限制

執行摘要

  • 全球市場展望
  • 供需趨勢分析
  • 細分市場機會分析

市場動態與展望

  • 市場規模
  • 市場動態
    • 促進因素和機遇
    • 限制與挑戰
  • 波特分析

關鍵市場考察

  • 關鍵成功因素
  • 競爭程度
  • 關鍵投資機會
  • 市場生態系統
  • 市場吸引力指數（2025）
  • PESTEL 分析
  • 總體經濟指標
  • 價值鏈分析
  • 定價分析

全球植入胰島素幫浦市場規模（按幫浦類型和複合年成長率分類）（2026-2033 年）

  • 可程式設計植入式泵
  • 閉合迴路泵
  • 開放回路泵
  • 非可程式設計植入式泵
  • 其他

全球植入胰島素幫浦市場規模（按儲液容量和複合年成長率分類）（2026-2033 年）

  • 小體積（10毫升或更少）
  • 中等容量（10-20毫升）
  • 大容量（超過20毫升）
  • 其他

全球植入胰島素幫浦市場規模（依給藥方式及複合年成長率分類）（2026-2033 年）

  • 持續基礎給藥
  • 大劑量投藥
  • 基礎和Bolus聯合給藥
  • 其他

全球植入胰島素幫浦市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）

  • 醫院
  • 門診手術中心（ASC）
  • 糖尿病專科診所
  • 居家醫療環境
  • 其他

全球植入胰島素幫浦市場規模（依年齡層分類）及複合年成長率（2026-2033 年）

  • 兒童（17歲及以下）
  • 成年人（18-64歲）
  • 老年人（65歲以上）

全球植入胰島素幫浦市場規模（按適應症和複合年成長率分類）（2026-2033 年）

  • 1型糖尿病（T1DM）
  • 2型糖尿病（T2DM）
  • 其他

全球植入胰島素幫浦市場規模（依通路分類）及複合年成長率（2026-2033 年）

  • 兒童（17歲及以下）
  • 成年人（18-64歲）
  • 老年人（65歲以上）

全球植入胰島素幫浦市場規模（按地區分類）及複合年成長率（2026-2033 年）

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 西班牙
    • 法國
    • 英國
    • 義大利
    • 其他歐洲地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地區
  • 中東和非洲
    • 海灣合作理事會國家
    • 南非
    • 其他中東和非洲地區

競爭資訊

  • 前五大公司對比
  • 主要企業的市場定位（2025 年）
  • 主要市場參與者所採取的策略
  • 近期市場趨勢
  • 公司市佔率分析（2025 年）
  • 主要企業公司簡介
    • 公司詳情
    • 產品系列分析
    • 依業務板塊進行公司股票分析
    • 2023-2025年營收年比比較

主要企業簡介

  • Medtronic Plc.（Ireland）
  • Insulet Corporation（United States）
  • Tandem Diabetes Care, Inc.（United States）
  • F. Hoffmann-La Roche AG（Switzerland）
  • Ypsomed AG（Switzerland）
  • SOOIL Development Co., Ltd.（South Korea）
  • Novo Nordisk（Denmark）
  • Johnson & Johnson（United States）
  • Bigfoot Biomedical, Inc.（United States）
  • Beta Bionics（United States）
  • Diabeloop SACA（France）
  • Debiotech SA（Switzerland）
  • Terumo Corporation（Japan）
  • Wuxi Apex Medical Co., Ltd.（China）
  • ViCentra BV（Netherlands）
  • CeQur（Switzerland）
  • Medtrum Technologies Inc.（China）
  • MicroPort Scientific（China）
  • Menarini Diagnostics Srl（Italy）
  • Ascensia Diabetes Care（Switzerland）

結論與建議

簡介目錄
Product Code: SQMIG35A3126

Global Implantable Insulin Pump Market size was valued at USD 39.35 Billion in 2024 and is poised to grow from USD 48.08 Billion in 2025 to USD 239.09 Billion by 2033, growing at a CAGR of 22.2% during the forecast period (2026-2033).

The global implantable insulin pump market is experiencing significant growth fueled by the increasing prevalence of diabetes and a rising demand for sophisticated insulin delivery systems. Patients are opting for continuous and precise insulin management, driven by a desire to minimize blood sugar fluctuations and long-term complications. Technological advancements have led to more reliable, user-friendly pump designs, while heightened awareness of effective diabetes management strategies supports market expansion. Additionally, favorable healthcare policies and reimbursement programs are making these devices more accessible. However, challenges such as high costs associated with the pumps and surgical procedures, limited awareness in developing regions, rigorous regulatory requirements, potential infection risks, and ongoing maintenance needs may hinder market growth in the near future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Implantable Insulin Pump market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Implantable Insulin Pump Market Segments Analysis

Global Implantable Insulin Pump Market is segmented by Pump Type, Reservoir Size, Delivery Mode, End User, Age Group, Indication, Distribution Channel and region. Based on Pump Type, the market is segmented into Programmable Implantable Pumps, Closed-loop Pumps, Open-loop Pumps, Non-programmable Implantable Pumps and Others. Based on Reservoir Size, the market is segmented into Small Volume (<=10 mL), Medium Volume (10-20 mL), Large Volume (>20 mL) and Others. Based on Delivery Mode, the market is segmented into Continuous Basal Delivery, Bolus Delivery, Combined Basal-Bolus Delivery and Others. Based on End User, the market is segmented into Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Diabetes Clinics, Homecare Settings and Others. Based on Age Group, the market is segmented into Pediatric (<=17 years), Adults (18-64 years) and Geriatric (>=65 years). Based on Indication, the market is segmented into Type 1 Diabetes Mellitus (T1DM), Type 2 Diabetes Mellitus (T2DM) and Others. Based on Distribution Channel, the market is segmented into Pediatric (<=17 years), Adults (18-64 years) and Geriatric (>=65 years). Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Implantable Insulin Pump Market

One of the key market drivers for the global implantable insulin pump market is the rising prevalence of diabetes worldwide, particularly type 1 diabetes. As awareness of diabetes management and the importance of maintaining optimal blood glucose levels increases, there is a growing demand for advanced diabetes care solutions, such as implantable insulin pumps. These devices not only enhance patient convenience by providing continuous insulin delivery but also improve glycemic control, thereby reducing the risk of complications associated with diabetes. Additionally, technological advancements and innovations in pump designs are further propelling the adoption of these devices among patients seeking effective management options.

Restraints in the Global Implantable Insulin Pump Market

One significant market restraint for the global implantable insulin pump market is the high cost associated with these advanced medical devices. The initial purchase price, coupled with ongoing expenses for maintenance, supplies, and healthcare consultations, can be prohibitive for many patients, particularly in developing regions where healthcare funding is limited. Additionally, the reimbursement landscape is often inconsistent, leading to financial barriers for patients seeking access to these innovative technologies. This economic challenge may deter adoption rates and limit the growth potential of the implantable insulin pump market, impacting both manufacturers and end-users seeking effective diabetes management solutions.

Market Trends of the Global Implantable Insulin Pump Market

The global implantable insulin pump market is experiencing a significant trend towards the integration of advanced technologies, particularly continuous glucose monitoring (CGM) systems. This synergy is leading to the development of closed-loop systems, often considered artificial pancreas solutions, which enable automatic insulin delivery adjustments based on real-time glucose readings. Such innovations are not only enhancing treatment precision but also simplifying daily management for users, reducing the need for constant monitoring and manual input. Consequently, the market is witnessing a growing demand for these smart implantable devices, which boost patient confidence and improve overall diabetes management outcomes.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2025
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis

Global Implantable Insulin Pump Market Size by Pump Type & CAGR (2026-2033)

  • Market Overview
  • Programmable Implantable Pumps
  • Closed-loop Pumps
  • Open-loop Pumps
  • Non-programmable Implantable Pumps
  • Others

Global Implantable Insulin Pump Market Size by Reservoir Size & CAGR (2026-2033)

  • Market Overview
  • Small Volume (<=10 mL)
  • Medium Volume (10-20 mL)
  • Large Volume (>20 mL)
  • Others

Global Implantable Insulin Pump Market Size by Delivery Mode & CAGR (2026-2033)

  • Market Overview
  • Continuous Basal Delivery
  • Bolus Delivery
  • Combined Basal-Bolus Delivery
  • Others

Global Implantable Insulin Pump Market Size by End User & CAGR (2026-2033)

  • Market Overview
  • Hospitals
  • Ambulatory Surgical Centers (ASCs)
  • Specialty Diabetes Clinics
  • Homecare Settings
  • Others

Global Implantable Insulin Pump Market Size by Age Group & CAGR (2026-2033)

  • Market Overview
  • Pediatric (<=17 years)
  • Adults (18-64 years)
  • Geriatric (>=65 years)

Global Implantable Insulin Pump Market Size by Indication & CAGR (2026-2033)

  • Market Overview
  • Type 1 Diabetes Mellitus (T1DM)
  • Type 2 Diabetes Mellitus (T2DM)
  • Others

Global Implantable Insulin Pump Market Size by Distribution Channel & CAGR (2026-2033)

  • Market Overview
  • Pediatric (<=17 years)
  • Adults (18-64 years)
  • Geriatric (>=65 years)

Global Implantable Insulin Pump Market Size & CAGR (2026-2033)

  • North America (Pump Type, Reservoir Size, Delivery Mode, End User, Age Group, Indication, Distribution Channel)
    • US
    • Canada
  • Europe (Pump Type, Reservoir Size, Delivery Mode, End User, Age Group, Indication, Distribution Channel)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Pump Type, Reservoir Size, Delivery Mode, End User, Age Group, Indication, Distribution Channel)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Pump Type, Reservoir Size, Delivery Mode, End User, Age Group, Indication, Distribution Channel)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Pump Type, Reservoir Size, Delivery Mode, End User, Age Group, Indication, Distribution Channel)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2025
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2025
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

  • Medtronic Plc. (Ireland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Insulet Corporation (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Tandem Diabetes Care, Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • F. Hoffmann-La Roche AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ypsomed AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • SOOIL Development Co., Ltd. (South Korea)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novo Nordisk (Denmark)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson & Johnson (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bigfoot Biomedical, Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Beta Bionics (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Diabeloop SACA (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Debiotech S.A. (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Terumo Corporation (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Wuxi Apex Medical Co., Ltd. (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • ViCentra B.V. (Netherlands)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • CeQur (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Medtrum Technologies Inc. (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • MicroPort Scientific (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Menarini Diagnostics S.r.l. (Italy)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ascensia Diabetes Care (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations